Genenta Science S.P.A. ADR (GNTA) Stock Price, Quote & News

Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, develops hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company offers Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is developing Temferon for use in the treatment of other solid tumor indications. In addition, the company develops biologic platform to deliver immunomodulatory molecules...

Industry: Biotechnology

Sector: Healthcare

Website: www.genenta.com

Address:

Via Olgettina No. 58, Milan, Italy

mcewing Aug. 4 at 5:38 PM

$GNTA down 10% in a raging bull

0 · Reply

DonCorleone77 Jul. 23 at 11:07 AM

$GNTA Sophia unveils Roman robotic arm to inspect nuclear fusion machine operations Sophia High Tech, backed by Genenta Science, announced the unveiling of Roman, a robotic arm engineered to perform inspection and maintenance operations inside a nuclear fusion machine. Sophia HT and its partners Department of Industrial Engineering and Herobots designed, developed, produced, assembled, tested and integrated the manipulator Roman units for two facilities: the DII of the University Federico II and to Consorzio RFX2.

0 · Reply

Fakhrul123 Jul. 23 at 8:15 AM

$GNTA Genenta-Backed Sòphia High Tech Unveils ROMAN Robotic Arm For Nuclear Fusion Reactor Inspection And Maintenance

0 · Reply

Fakhrul123 Jul. 23 at 7:14 AM

$GNTA $5 soon

0 · Reply

mcewing Jul. 22 at 10:24 AM

$GNTA new division increases sales and operating profit. Good

0 · Reply

Sarah147 Jul. 20 at 6:00 PM

$GNTA Has a very small market capitalization*

0 · Reply

topstockalerts Jul. 17 at 12:50 PM

$GNTA not chasing, but definitely respecting the move

0 · Reply

Zardiw Jul. 15 at 4:08 PM

$SOBR up 65% - Flagged early by DDAmanda. Chart: Also found early: $TGHL $VIVS $GNTA Never miss another: https://DDAmanda.com/

0 · Reply

vcaelum Jul. 15 at 1:37 PM

$GNTA in 1.57 HARD SL on LOD 1.41

0 · Reply

Terryone907 Jul. 13 at 11:25 PM

$GNTA is this scam?

1 · Reply

Sophia unveils Roman robotic arm to inspect nuclear fusion machine operations

Jul 23, 2026, 3:09 AM EDT - 15 days ago

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

Jul 22, 2026, 4:00 AM EDT - 16 days ago

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

Apr 23, 2026, 7:00 AM EDT - 3 months ago

Genenta signs Definitive Agreements with Sophia High Tech

2026-03-27T09:05:10.000Z - 4 months ago

Genenta Science enters binding offer to fund Sophia High Tech

Mar 27, 2026, 5:00 AM EDT - 4 months ago

Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

Mar 24, 2026, 3:27 AM EDT - 4 months ago

Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

Mar 13, 2026, 5:00 AM EDT - 5 months ago

Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University

Feb 27, 2026, 4:00 AM EST - 5 months ago

Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform

2026-01-27T10:25:23.000Z - 6 months ago

Genenta Science to change name to Saentra Forge, seeks controlling stake in ATC

Jan 27, 2026, 3:00 AM EST - 6 months ago

Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator

Dec 19, 2025, 2:30 AM EST - 8 months ago

Genenta Science Provides Update on CEO Ownership

2025-11-24T10:10:13.000Z - 9 months ago

Genenta Science provides update from TEM-GBM study

Nov 24, 2025, 4:00 AM EST - 9 months ago

Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial

Oct 26, 2025, 8:30 PM EDT - 10 months ago

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

2025-10-24T12:36:37.000Z - 10 months ago

Why Is Genenta Science Stock (GNTA) Up 275% Today?

2025-10-24T09:10:19.000Z - 10 months ago

Genenta Science, Anemocyte enter pact to advance Plasmid DNA technology

Oct 24, 2025, 4:00 AM EDT - 10 months ago

Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production

2025-07-01T09:25:53.000Z - 1 year ago

Genenta Science announces follow-up observations in glioblastoma study

Jul 1, 2025, 5:00 AM EDT - 1 year ago

Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals

May 8, 2025, 7:00 AM EDT - 1 year ago

Genenta Science, SpA Announces Participation in the D. Boral Capital Inaugural Global Conference

2025-05-07T11:43:50.000Z - 1 year ago

Genenta Science, Anemocyte announce collaboration

May 7, 2025, 7:00 AM EDT - 1 year ago

Genenta and Anemocyte announce a collaboration for the manufacturing of starting materials for cutting-edge cell-based therapies

Apr 15, 2025, 5:00 AM EDT - 1 year ago

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

2025-03-19T13:37:19.000Z - 1 year ago

Genenta Science announces EUR 20M financing to expand pipeline

Mar 19, 2025, 9:28 AM EDT - 1 year ago

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

Jan 28, 2025, 8:01 AM EST - 1 year ago

TOP ITALIAN AND U.S. LIFE SCIENCES EXECUTIVES AND ITALIAN GOVERNMENT LEADERS SHARED BUSINESS SUCCESS STORIES WITH INVESTORS AT "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

2025-01-09T11:51:43.000Z - 1 year ago

Genenta Science announces amendment to pact with AGC Biologics

Jan 9, 2025, 6:00 AM EST - 1 year ago

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Jan 8, 2025, 3:17 PM EST - 1 year ago

ITALIAN TRADE AGENCY TO HOST "ITALY ON THE MOVE 2025" SIDE EVENT DURING J.P. MORGAN HEALTHCARE CONFERENCE

2024-11-29T14:45:23.000Z - 1 year ago

Genenta Science SPA (ADR) trading resumes

2024-11-29T14:35:20.000Z - 1 year ago

Genenta Science SPA (ADR) trading halted, volatility trading pause

2024-10-23T11:20:34.000Z - 1 year ago

Genenta Science CEO to present at U.S. Senate meeting

Oct 23, 2024, 7:00 AM EDT - 1 year ago

Genenta's CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

2024-10-21T14:17:06.000Z - 1 year ago

Genenta Science SPA (ADR) trading resumes

2024-10-10T13:55:20.000Z - 1 year ago

Genenta Science SPA (ADR) trading resumes

2024-10-10T13:50:09.000Z - 1 year ago

Genenta Science SPA (ADR) trading halted, volatility trading pause

2024-10-02T10:42:04.000Z - 2 years ago

Genenta Science secures approval for trial for metastatic Renal Cell Cancer

Oct 2, 2024, 6:30 AM EDT - 2 years ago

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

May 6, 2024, 6:25 AM EDT - 2 years ago

Genenta Welcomes New Directors John L. Cantello, Lauren H.

2024-02-08T10:05:35.000Z - 2 years ago

Genenta Science doses first three TEM-GBM patients in Cohort 8

Feb 8, 2024, 5:00 AM EST - 2 years ago

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Sep 6, 2023, 7:00 AM EDT - 3 years ago

Genenta to Present at Upcoming Scientific and Investor Conferences

Jul 28, 2023, 3:00 AM EDT - 3 years ago

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jun 29, 2023, 7:00 AM EDT - 3 years ago

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Apr 26, 2023, 7:00 AM EDT - 3 years ago

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 3, 2023, 7:00 AM EDT - 3 years ago

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Mar 2, 2023, 6:45 AM EST - 3 years ago

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

Feb 7, 2023, 7:00 AM EST - 3 years ago

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

Nov 7, 2022, 8:05 AM EST - 4 years ago

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

Oct 24, 2022, 7:30 AM EDT - 4 years ago

Genenta Provides First Half 2022 Business Update and Financial Results

Sep 7, 2022, 7:00 AM EDT - 4 years ago

Genenta to Present at Upcoming Investor Conferences

Jul 25, 2022, 6:00 AM EDT - 4 years ago

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

May 13, 2022, 7:30 AM EDT - 4 years ago

Genenta to Present at Upcoming Scientific Congresses ASGCT, BTM, ASCO and EHA

May 9, 2022, 7:30 AM EDT - 4 years ago

Genenta Appoints Industry Veteran Tim Obara as Head of Business Development

May 4, 2022, 4:30 PM EDT - 4 years ago

Genenta Files Annual Report on Form 20-F for Fiscal Year 2021

May 4, 2022, 7:30 AM EDT - 4 years ago

Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme

May 2, 2022, 4:30 PM EDT - 4 years ago

Genenta ASGCT Clinical Data Highlights Temferon™ Biological Effects in Glioblastoma

Apr 27, 2022, 7:30 AM EDT - 4 years ago

Genenta Announces Nomination of Mark A. Sirgo as Chair

Apr 20, 2022, 7:30 AM EDT - 4 years ago

Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors

Mar 9, 2022, 7:46 AM EST - 4 years ago

Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon™ in Unmethylated Glioblastoma Multiforme

Feb 24, 2022, 7:30 AM EST - 4 years ago

Genenta to Participate at Upcoming Investor Conferences

Dec 17, 2021, 4:15 PM EST - 5 years ago

Genenta Closes Its Upsized Initial Public Offering of American Depository Shares

Dec 14, 2021, 10:36 PM EST - 5 years ago

Genenta Announces Pricing of Upsized Initial Public Offering

mcewing Aug. 4 at 5:38 PM

$GNTA down 10% in a raging bull

0 · Reply

DonCorleone77 Jul. 23 at 11:07 AM

0 · Reply

Fakhrul123 Jul. 23 at 8:15 AM

$GNTA Genenta-Backed Sòphia High Tech Unveils ROMAN Robotic Arm For Nuclear Fusion Reactor Inspection And Maintenance

0 · Reply

Fakhrul123 Jul. 23 at 7:14 AM

$GNTA $5 soon

0 · Reply

mcewing Jul. 22 at 10:24 AM

$GNTA new division increases sales and operating profit. Good

0 · Reply

Sarah147 Jul. 20 at 6:00 PM

$GNTA Has a very small market capitalization*

0 · Reply

topstockalerts Jul. 17 at 12:50 PM

$GNTA not chasing, but definitely respecting the move

0 · Reply

Zardiw Jul. 15 at 4:08 PM

$SOBR up 65% - Flagged early by DDAmanda. Chart: Also found early: $TGHL $VIVS $GNTA Never miss another: https://DDAmanda.com/

0 · Reply

vcaelum Jul. 15 at 1:37 PM

$GNTA in 1.57 HARD SL on LOD 1.41

0 · Reply

Terryone907 Jul. 13 at 11:25 PM

$GNTA is this scam?

1 · Reply

mcewing Jul. 10 at 7:44 PM

$GNTA we need some good news here. Due for a pop.

0 · Reply

focafoca99 Jun. 24 at 1:25 PM

$GNTA outlines a severance agreement for CEO Pierluigi Paracchi and amends his non‑compete covenant.

1 · Reply

TheUnmaker Jun. 22 at 10:35 AM

$ADTX $PFSA $RGNX $GNTA $CNTX

0 · Reply

DylanGFM Jun. 22 at 8:54 AM

$GNTA todays just not your day is it buddy. see you later.

0 · Reply

DylanGFM Jun. 22 at 8:51 AM

$EHGO this is beautiful scalping PA I must say. Glad I chose the 4am route hahaha.. doesn't always pay off but it is hot right now and maybe $GNTA tries to break above the gap up its sitting with support on the 5 min. could get another huge stretched out field goal on the daily like with $GETY

0 · Reply

Fakhrul123 Jun. 22 at 1:02 AM

$GNTA

0 · Reply

focafoca99 Jun. 16 at 1:27 PM

$GNTA regained compliance with Nasdaq's $1.00 minimum bid price rule.

0 · Reply

jucebot Jun. 11 at 12:57 PM

Jovanotti just got long on $GNTA @ $1.87 $AMAU $DAIC $ICON $TGHL

0 · Reply

jucebot Jun. 11 at 9:21 AM

FJ is in a long on $GNTA @ $1.92 $DBGI

0 · Reply

jucebot Jun. 11 at 8:46 AM

FJ entered a long on $AMBO @ $3.10 $DBGI $FLYT $GNTA

0 · Reply

jucebot Jun. 11 at 8:43 AM

FJ just opened a long in $FLYT @ $18.10 $DBGI $GNTA $KDK $RFL

0 · Reply

jucebot Jun. 11 at 8:42 AM

FJ entered a long on $KDK @ $6.55 $DBGI $GNTA $RFL

0 · Reply

Market Cap	31.38M
Revenue (ttm)	0.00
Net Income (ttm)	-7.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	45,214
Avg Vol	1,828,308
Day's Range	N/A - N/A
Shares Out	23.59M
Stochastic %K	22%
Beta	0.77
Analysts	Strong Buy
Price Target	$7.00